Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Breakthrough treatments for hereditary angioedema revealed at EAACI 2024
endoscopic procedure duodenum
JOURNALS
Start Learning
Novel strategy shows potential to reduce insulin dependence in type 2 diabetes
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of lupus and Sjögren’s disease
Sponsored content
A 3D model of an elbow joint is shown, highlighting areas of pain and inflammation with bright red and orange colors. Generative AI.
JOURNALS
Start Learning
Hypermobility Spectrum Disorders and Pain: A Review of Recent Developments and their Application to Clinical Practice 
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
infliximab ulcerative colitis
JOURNALS
Start Learning
Increased infliximab clearance in patients hospitalized with severe ulcerative colitis may lead to underexposure
Luis Felipe Ensina, leading innovation in allergy and immunology
JOURNALS
Start Learning
Global Impact, Brazilian Roots: Prof. Ensina’s Journey Leading Innovation in Allergy and Immunology
JOURNALS
Start Learning
Bridging Bench and Bedside: Future Leader, Dr Sonali Bracken on Autoimmunity, B Cell Research, and the Future of Rheumatology
touchIN CONVERSATION
Start Learning
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
#EULAR2025 Sonelokimab Shows Promise in Improving PROs for Psoriatic Arthritis: Phase II ARGO Trial

to view Favourites, Keep Notes and Track CME Credits

Favourites
Novel strategy shows potential to reduce insulin dependence in type 2 diabetes
View
Novel anti-CD6 monoclonal antibody, itolizumab, showcases proof of concept in ulcerative colitis
View
Highlights from EULAR 2024: Advancing rheumatology
View
Advancing Clinical Care and Research in Paediatric Gastroenterology: An Interview with Future Leader, Dr Salvatore Oliva
View
Clinical Phenotyping and Molecular Endotyping in Osteoarthritis – Personalised Approaches to Therapeutics: Ali Mobasheri, WCO-IOF-ESCEO 2025
View
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
View
Advancing Osteoarthritis Research Through Immunology and Clinical Insight: An Interview with Future Leader, Dr Tom Appleton
View
Efficacy of secukinumab as first-line bDMARD vs standard-of-care
View
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
View
Honouring Prof. Marcus Maurer
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup